Dr. Kenneth Mahaffey, MD

Cardiovascular Disease Stanford, CA Male
NPI: 1659455707
Total Payments
$787,234
2024 Payments
$118,416
Companies
23
Transactions
382
Medicare Patients
1,644
Medicare Billing
$50,016

Payment Breakdown by Category

Consulting$564,792 (71.7%)
Research$123,685 (15.7%)
Travel$69,822 (8.9%)
Other$21,763 (2.8%)
Food & Beverage$7,173 (0.9%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $564,792 130 71.7%
Unspecified $123,685 51 15.7%
Travel and Lodging $69,822 76 8.9%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,693 3 2.1%
Food and Beverage $7,173 120 0.9%
Honoraria $5,070 2 0.6%

Payments by Type

General
$663,549
331 transactions
Research
$123,685
51 transactions

Top Paying Companies

Company Total Records Latest Year
Janssen Research & Development, LLC $241,329 130 $0 (2024)
Novo Nordisk AS $116,526 33 $0 (2024)
Boehringer Ingelheim RCV GmbH & Co KG $101,500 21 $0 (2018)
GlaxoSmithKline, LLC. $82,356 8 $0 (2017)
E.R. Squibb & Sons, L.L.C. $47,165 15 $0 (2024)
Otsuka Pharmaceutical Development & Commercialization, Inc. $31,680 18 $0 (2022)
CSL Behring $29,368 15 $0 (2022)
Janssen Global Services, LLC $28,478 23 $0 (2020)
Bayer Healthcare Pharmaceuticals Inc. $26,979 22 $0 (2023)
AstraZeneca Pharmaceuticals LP $22,975 11 $0 (2020)

Payment History by Year

Year Amount Transactions Top Company
2024 $118,416 60 Novo Nordisk AS ($44,682)
2023 $50,449 38 Janssen Research & Development, LLC ($18,891)
2022 $137,969 43 Janssen Research & Development, LLC ($68,990)
2021 $73,222 28 Janssen Research & Development, LLC ($34,775)
2020 $53,443 33 Janssen Research & Development, LLC ($17,875)
2019 $75,853 54 Janssen Research & Development, LLC ($27,377)
2018 $110,747 56 Boehringer Ingelheim RCV GmbH & Co KG ($56,250)
2017 $167,137 70 GlaxoSmithKline, LLC. ($82,356)

All Payment Transactions

382 individual payment records from CMS Open Payments — Page 1 of 16

Date Company Product Nature Form Amount Type
11/13/2024 E.R. Squibb & Sons, L.L.C. CAMZYOS (Drug) Consulting Fee Cash or cash equivalent $3,640.00 General
Category: Cardiovascular
11/07/2024 E.R. Squibb & Sons, L.L.C. CAMZYOS (Drug) Consulting Fee Cash or cash equivalent $4,550.00 General
Category: Cardiovascular
10/09/2024 ModernaTX, Inc. — Consulting Fee Cash or cash equivalent $1,250.00 General
09/30/2024 Eli Lilly and Company — Consulting Fee Cash or cash equivalent $3,800.00 General
08/30/2024 Novo Nordisk AS — Travel and Lodging In-kind items and services $473.28 General
08/29/2024 Janssen Research & Development, LLC — Food and Beverage In-kind items and services $57.54 General
08/28/2024 Janssen Research & Development, LLC — Food and Beverage In-kind items and services $38.23 General
08/21/2024 ModernaTX, Inc. — Consulting Fee Cash or cash equivalent $1,500.00 General
06/24/2024 Novo Nordisk AS — Travel and Lodging In-kind items and services $1,093.33 General
06/24/2024 Novo Nordisk AS — Travel and Lodging In-kind items and services $858.00 General
06/24/2024 Novo Nordisk AS — Travel and Lodging In-kind items and services $300.46 General
06/24/2024 Novo Nordisk AS — Food and Beverage In-kind items and services $173.31 General
05/31/2024 Eli Lilly and Company — Consulting Fee Cash or cash equivalent $4,400.00 General
05/23/2024 Novo Nordisk AS Ozempic (Drug) — In-kind items and services $9,752.12 Research
Study: NN9535-4321 • Category: Diabetes
05/23/2024 Novo Nordisk AS Ozempic (Drug) — Cash or cash equivalent $9,106.25 Research
Study: NN9535-4321 • Category: Diabetes
05/23/2024 Novo Nordisk AS Ozempic (Drug) — In-kind items and services $703.59 Research
Study: NN9535-4321 • Category: Diabetes
05/23/2024 Novo Nordisk AS Ozempic (Drug) — Cash or cash equivalent $245.25 Research
Study: NN9535-4321 • Category: Diabetes
05/17/2024 E.R. Squibb & Sons, L.L.C. CAMZYOS (Drug) Consulting Fee Cash or cash equivalent $4,160.00 General
Category: Cardiovascular
05/07/2024 E.R. Squibb & Sons, L.L.C. CAMZYOS (Drug) Consulting Fee Cash or cash equivalent $2,300.00 General
Category: Cardiovascular
04/29/2024 E.R. Squibb & Sons, L.L.C. CAMZYOS (Drug) Consulting Fee Cash or cash equivalent $5,200.00 General
Category: Cardiovascular
04/26/2024 Janssen Research & Development, LLC — Travel and Lodging In-kind items and services $148.36 General
04/26/2024 Janssen Research & Development, LLC — Travel and Lodging In-kind items and services $148.36 General
04/26/2024 Janssen Research & Development, LLC — Travel and Lodging In-kind items and services $148.36 General
04/26/2024 Janssen Research & Development, LLC — Travel and Lodging Cash or cash equivalent $100.00 General
04/26/2024 Janssen Research & Development, LLC — Travel and Lodging Cash or cash equivalent $100.00 General
123…16»

Research Studies & Clinical Trials

Study Name Company Amount Records
NN9535-4321 Novo Nordisk AS $87,865 17
PHASE 3B, RANDOMIZED, OPEN-LABEL, SPONSOR-BLIND, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT, ONCE DAILY (QD) AND THREE TIMES WEEKLY (TIW) FOR THE MAINTENANCE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) Otsuka Pharmaceutical Development & Commercialization, Inc. $18,360 11
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk SANOFI US SERVICES INC. $6,700 5
EFPEG CVOT SANOFI US SERVICES INC. $5,105 6
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular SANOFI US SERVICES INC. $4,745 3
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) SANOFI US SERVICES INC. $260.00 2
A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr SANOFI US SERVICES INC. $195.00 1
A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin SANOFI US SERVICES INC. $130.00 2
EFPEG non-outcomes SANOFI US SERVICES INC. $130.00 1
A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea SANOFI US SERVICES INC. $65.00 1
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr SANOFI US SERVICES INC. $65.00 1
A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Dia SANOFI US SERVICES INC. $65.00 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 7 210 241 $62,344 $11,369
2022 7 485 577 $89,156 $15,304
2021 7 644 761 $99,324 $15,630
2020 5 305 348 $40,771 $7,712
Total Patients
1,644
Total Services
1,927
Medicare Billing
$50,016
Procedure Codes
26

All Medicare Procedures & Services

26 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 22 27 $22,062 $4,413 20.0%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 18 27 $7,290 $1,970 27.0%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 13 15 $9,912 $1,597 16.1%
99221 Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes Facility 2023 15 15 $5,385 $1,058 19.7%
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes Facility 2023 19 22 $3,740 $993.52 26.6%
93010 Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only Facility 2023 98 109 $6,649 $762.97 11.5%
93248 Heart rhythm review and interpretation of continous external ekg over 8-15 days Facility 2023 25 26 $7,306 $574.69 7.9%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 29 47 $17,296 $4,413 25.5%
93010 Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only Facility 2022 353 408 $24,888 $3,014 12.1%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 12 16 $14,560 $2,502 17.2%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 31 39 $9,724 $2,338 24.0%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 16 20 $14,276 $2,004 14.0%
93248 Heart rhythm review and interpretation of continous external ekg over 8-15 days Facility 2022 26 26 $7,306 $597.63 8.2%
Q3014 Telehealth originating site facility fee Office 2022 18 21 $1,106 $435.68 39.4%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 21 32 $28,992 $4,723 16.3%
93010 Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report Facility 2021 535 623 $38,003 $4,678 12.3%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 14 20 $7,360 $1,909 25.9%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 24 29 $7,076 $1,881 26.6%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 13 14 $9,968 $1,487 14.9%
93248 Heart rhythm review and interpretation of continous external ekg over 8-15 days Facility 2021 24 25 $7,025 $585.12 8.3%
Q3014 Telehealth originating site facility fee Office 2021 13 18 $900.00 $367.54 40.8%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 14 21 $7,728 $2,044 26.5%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 22 29 $7,076 $1,999 28.3%
93010 Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report Facility 2020 236 264 $16,104 $1,875 11.6%
99221 Initial hospital inpatient care, typically 30 minutes per day Facility 2020 12 13 $4,667 $1,274 27.3%
12»

About Dr. Kenneth Mahaffey, MD

Dr. Kenneth Mahaffey, MD is a Cardiovascular Disease healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659455707.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Mahaffey, MD has received a total of $787,234 in payments from pharmaceutical and medical device companies, with $118,416 received in 2024. These payments were reported across 382 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($564,792).

As a Medicare-enrolled provider, Mahaffey has provided services to 1,644 Medicare beneficiaries, totaling 1,927 services with total Medicare billing of $50,016. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.

Practice Information

  • Specialty Cardiovascular Disease
  • Other Specialties Cardiovascular Disease
  • Location Stanford, CA
  • Active Since 10/25/2006
  • Last Updated 04/23/2024
  • Taxonomy Code 207RC0000X
  • Entity Type Individual
  • NPI Number 1659455707

Products in Payments

  • PRADAXA (Drug) $101,500
  • INVOKANA (Drug) $97,585
  • Ozempic (Drug) $79,615
  • CAMZYOS (Drug) $33,760
  • EPANOVA (Drug) $24,652
  • Kerendia (Drug) $18,372
  • NUCALA (Biological) $12,299
  • Non-Covered $5,363
  • PRALUENT (Biological) $3,570
  • XARELTO (Drug) $3,359
  • Moderna Covid-19 Vaccine (Biological) $3,000
  • EFPEGLENATIDE (Drug) $1,690
  • MODERNA COVID-19 VACCINE (Biological) $1,000
  • CRT-Ds (Device) $192.69
  • Repatha (Biological) $134.93
  • ENTRESTO (Drug) $100.72
  • PRALUENT (Drug) $97.00
  • PRALUENT ALIROCUMAB INJECTION (Biological) $70.00
  • BRILINTA (Drug) $25.73

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Cardiovascular Disease Doctors in Stanford

Dr. Wilber Su, Md, MD

Cardiovascular Disease — Payments: $1.1M

Cardiovascular Disease $1.1M

Dr. Todd Brinton, M.d, M.D

Cardiovascular Disease — Payments: $632,155

Cardiovascular Disease $632,155

Peter Fitzgerald, Md, MD

Cardiovascular Disease — Payments: $305,461

Cardiovascular Disease $305,461

David Lee, Md, MD

Cardiovascular Disease — Payments: $286,441

Cardiovascular Disease $286,441

Jeffrey Teuteberg, Md, MD

Cardiovascular Disease — Payments: $240,818

Cardiovascular Disease $240,818

Jennifer Tremmel, Md, MD

Cardiovascular Disease — Payments: $226,260

Cardiovascular Disease $226,260